Nutritional Effects on Mind and Mood 

Links to interesting material
Fatigue & Depression, Bipolar, Post-Partum depression,Schizophrenia, Pyroluria, OCD, Panic Disorder, Aggressive Disorder, ADD/ADHD, & Multiple Issues

The Failure of Conventional Treatment:
The following annual report from King County, Washington, home of the city of Seattle, shows how psychiatric drug treatment does not lead to recovery.  Of over 9300 patients treated by the county in 2002, only 5 individuals recovered.  The report for 2001 is similar
Second Annual Report: Recovery Model

 Mental health link to diet change BBC

Fatigue and Depression:
  1. Vitamin B-3: Niacin and It's Amide  Full Text
  2. Adams PB, Lawson S, Sanigorski A, Sinclair AJ.  Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.   Lipids. 1996 Mar; 31 Suppl: S157-61 Abstract
  3. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. Inositol treatment in psychiatry.  Psychopharmacol Bull. 1995; 31(1): 167-75  Abstract 
  4. Bitsas C.   Nutrients and Depression: Food for Your Mood. Health Research Institute and Pfeiffer Treatment Center  Full text 
  5. Bodnar LM, Wisner KL.  Nutrition and depression: implications for improving mental health among childbearing-aged women.  Biol Psychiatry. 2005 Nov 1; 58(9): 679-85.  Abstract 
  6. Casper RC.   Nutrients, neurodevelopment, and mood. Curr Psychiatry Rep. 2004 Dec; 6(6): 425-9 Abstract 
  7. Coupland NJ, Ogilvie CJ, Hegadoren KM, et al. Decreased prefrontal Myo-inositol in major depressive disorder.   Biol Psychiatry. 2005 Jun 15; 57(12): 1526-34.  Abstract 
  8. Docherty JP, Sack DA, Roffman M, et al.   A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving.    J Psychiatr Pract. 2005 Sep; 11(5): 302-14.  Abstract 
  9. Edwards R, Peet M, Shay J, Horrobin D.  Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients.   J Affect Disord. 1998 Mar; 48(2-3): 149-55 Abstract
  10. Fontani G, Corradeschi F, Felici A,et al.   Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects.    Eur J Clin Invest. 2005 Nov; 35(11): 691-9.   Abstract
  11. Fugh-Berman A, Cott JM.  Dietary supplements and natural products as psychotherapeutic agents.   Psychosom Med. 1999 Sep-Oct; 61(5): 712-28.   Abstract |  Full text 
  12. Hibbeln JR, Salem N Jr.  Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy.   Am J Clin Nutr. 1995 Jul; 62(1): 1-9     Abstract
  13. Jorde R, Waterloo K, Saleh F, et al.  Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels The Tromso study.    J Neurol. 2005 Nov 14;   Abstract 
  14. Kieser M, Szegedi A.   Predicting stable treatment response in patients with major depression treated with hypericum extract WS 5570/5572.  Pharmacopsychiatry. 2005 Sep; 38(5): 194-200.   Abstract 
  15. Lerner V, Kanevsky M, Dwolatzky T, et al.  Vitamin B(12) and folate serum levels in newly admitted psychiatric patients.   Clin Nutr. 2006 Feb; 25(1): 60-67.  Abstract
  16.   Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997 May; 7(2): 147-55  Abstract
  17. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression.   Am J Psychiatry. 1995 May; 152(5): 792-4   Abstract  |  Full text 
  18. Levine J, Stein D, Rapoport A, Kurtzman L.  High serum and cerebrospinal fluid Ca/Mg ratio in recently hospitalized acutely depressed patients. Neuropsychobiology. 1999; 39(2): 63-70.   Abstract 
  19. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H.  Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids.    J Affect Disord. 1996 Apr 26; 38(1): 35-46.  Abstract 
  20. Mamalakis G, Tornaritis M, Kafatos A.  Depression and adipose essential polyunsaturated fatty acids.   Prostaglandins Leukot Essent Fatty Acids. 2002 Nov; 67(5): 311-8.  Abstract 
  21. Nemets H, Nemets B, Apter A, et al.   Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006 Jun; 163(6): 1098-100.   Abstract
  22. [No authors listed]   DHEA: over-the-counter antidote for depression. Non-prescription hormonal supplement can help relieve minor and major depression in middle age.   Health News. 2005 Jun; 11(6): 12-3 Citation 
  23. Obradovic D, Gronemeyer H, Lutz B, Rein T.   Cross-talk of vitamin D and glucocorticoids in hippocampal cells.   J Neurochem. 2006 Jan; 96(2): 500-9.   Abstract 
  24. Parker GB, Heruc GA, Hilton TM, et al.    Low levels of docosahexaenoic acid identified in acute coronary syndrome patients with depression.    Psychiatry Res. 2006 Feb 22  Abstract 
  25. Peet M, Horrobin DF.  A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.   Arch Gen Psychiatry. 2002 Oct; 59(10): 913-9   Abstract 
  26. Pouwer F, Nijpels G, Beekman AT, et al.     Fat food for a bad mood. Could we treat and prevent depression in Type 2 diabetes by means of omega-3 polyunsaturated fatty acids? A review of the evidence.  Diabet Med. 2005 Nov;22(11): 1465-75.  Abstract 
  27. Schmidt PJ, Daly RC, Bloch M, et al.  Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.   Arch Gen Psychiatry. 2005 Feb; 62(2): 154-62.   Abstract 
  28. Sontrop J, Campbell MK.   Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med. 2006 Jan; 42(1): 4-13.   Abstract 
  29. Su KP, Huang SY, Chiu CC, Shen WW.  Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.  Eur Neuropsychopharmacol. 2003 Aug; 13(4): 267-71  Abstract 
  30. Szegedi A, Kohnen R, Dienel A, Kieser M.    Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.    BMJ. 2005 Mar 5; 330(7490): 503. Abstract |  Full text 
  31. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E.  Fish consumption and depressive symptoms in the general population in Finland.   Psychiatr Serv. 2001 Apr; 52(4): 529-31.   Abstract |  Full text 
  32. Westover AN, Marangell LB.   A cross-national relationship between sugar consumption and major depression?  Depress Anxiety. 2002; 16(3): 118-20.   Abstract 
  33. Natural Products in the Clinical Treatment of Mental Illness:  A Profile of Dr. James Greenblatt, MD  [depression, panic disorder, and obsessive-compulsive disorder (OCD)] Full text 
Bipolar Disorder:
  1. ABC news story transcript  http://www.lorenbennett.org/nabcpig.htm 
  2. Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein RP, Agam G. Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. Bipolar Disord. 2002 Feb; 4(1): 67-9. Abstract 
  3. Bourre JM.  Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress, depression, dementia and aging.    J Nutr Health Aging. 2005; 9(1): 31-8.  Abstract 
  4. Chengappa KN, Levine J, Gershon S, et al.   Inositol as an add-on treatment for bipolar depression.   Bipolar Disord. 2000 Mar; 2(1): 47-55.  Abstract 
  5. Colin A, Reggers J, Castronovo V, Ansseau M.  [Lipids, depression and suicide]   Encephale. 2003 Jan-Feb; 29(1):  49-58. Abstract 
  6. Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG.  Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder.   J Clin Psychiatry. 2001 Dec; 62(12): 936-44.  Abstract 
  7. Kidd PM.  Bipolar disorder and cell membrane dysfunction. Progress toward integrative management.   Altern Med Rev. 2004 Jun; 9(2): 107-35.  Abstract  |  Full text 
  8. Noaghiul S, Hibbeln JR.   Cross-national comparisons of seafood consumption and rates of bipolar disorders.   Am J Psychiatry. 2003 Dec; 160(12): 2222-7   Abstract 
  9. Osher Y, Bersudsky Y, Belmaker RH.   Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study.  J Clin Psychiatry. 2005 Jun; 66(6): 726-9.   Abstract 
  10. Parker G, Gibson NA, Brotchie H, et al.   Omega-3 fatty acids and mood disorders.   Am J Psychiatry. 2006 Jun; 163(6): 969-78.   Abstract 
  11. Reid SD.   Pseudodementia in a twenty-one-year-old with bipolar disorder and vitamin B12 and folate deficiency.   West Indian Med J. 2000 Dec; 49(4): 347-8.  Abstract 
  12. Sagduyu K, Dokucu ME, Eddy BA, et al. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study.   Nutr J. 2005 Feb 09; 4(1): 6.  Abstract  |  Full text 
  13. Saugstad LF.  Manic depressive psychosis and schizophrenia are neurological disorders at the extremes of CNS maturation and nutritional disorders associated with a deficit in marine fat.   Med Hypotheses. 2001 Dec; 57(6): 679-92.  Abstract 
  14. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder.    Am J Psychiatry. 1997 Aug; 154(8): 1148-50.   Abstract  |  Full text 
  15. Stoll AL, Locke CA, Marangell LB, Severus WE.  Omega-3 fatty acids and bipolar disorder: a review.  Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun; 60(5-6): 329-37  Abstract
  16. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB.   Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.   Arch Gen Psychiatry. 1999 May; 56(5): 407-12   Abstract
Post-Partum depression:
  1. Abou-Saleh MT, Ghubash R, Karim L, et al.  The role of pterins and related factors in the biology of early postpartum depression.  Eur Neuropsychopharmacol. 1999 Jun; 9(4): 295-300.  Abstract 
  2. Beard JL, Hendricks MK, Perez EM, ET AL.  Maternal iron deficiency anemia affects postpartum emotions and cognition.   J Nutr. 2005 Feb; 135(2): 267-72.  Abstract | Full text 
  3. Chih-Chiang Chiu, M.D., Shih-Yi Huang, Ph.D., Winston W. Shen, M.D., And Kuan-Pin Su, M.D.  Omega-3 Fatty Acids for Depression in Pregnancy  Am J Psychiatry  2003 Feb; 160(2) 385   Full text 
  4. Corwin EJ, Murray-Kolb LE, Beard JL.  Low hemoglobin level is a risk factor for postpartum depression.   J Nutr. 2003 Dec; 133(12): 4139-42.   Abstract | Full text 
  5. De Vriese SR, Christophe AB, Maes M.  Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression.  Life Sci. 2003 Nov 7; 73(25): 3181-7.   Abstract
  6. Freeman MP, Hibbeln JR, Wisner KL, et al.  Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression.  Acta Psychiatr Scand. 2006 Jan; 113(1): 31-5.   Abstract
  7. Hibbeln JR.  Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis.   J Affect Disord. 2002 May; 69(1-3): 15-29. Abstract 
  8. Otto SJ, de Groot RH, Hornstra G.  Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status.   Prostaglandins Leukot Essent Fatty Acids. 2003 Oct; 69(4): 237-43.  Abstract 
 
Schizophrenia:
 
  1. Brochure of the International Schizophrenia Foundation
  2. Hoffer's Home Page -The Schizophrenias   Full text
  3. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA.  The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance.   Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun; 26(5): 995-1005.  Abstract 
  4. Applebaum J, Shimon H, Sela BA, et al.  Homocysteine levels in newly admitted schizophrenic patients.   J Psychiatr Res. 2004 Jul-Aug; 38(4): 413-6.  Abstract 
  5. Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia.   Schizophr Res. 2003 Aug 1; 62(3): 195-204.   Abstract 
  6. Benton D.  Selenium intake, mood and other aspects of psychological functioning.   Nutr Neurosci. 2002 Dec; 5(6): 363-74. Abstract 
  7. Boydell J, Van Os J, Lambri M, et al. Incidence of schizophrenia in south-east London between 1965 and 1997.   Br J Psychiatry. 2003 Jan; 182: 45-9.   Abstract |  Full text 
  8. Emsley R, Oosthuizen P, van Rensburg SJ.  Clinical potential of omega-3 fatty acids in the treatment of schizophrenia.  CNS Drugs. 2003; 17(15): 1081-91.  Abstract 
  9. Foster, HD.   What Really Causes Schizophrenia    Trafford Publishing. 2002
  10. Galton, G.  Why Young Adults Crack Up   Full text 
  11. Goff DC, Bottiglieri T, Arning E, et al.  Folate, homocysteine, and negative symptoms in schizophrenia.   Am J Psychiatry. 2004 Sep; 161(9): 1705-8.  Abstract 
  12. Hoffer, A   Inside Schizophrenia: Before and After Treatment.  J Orthomolecular Med 1996; 11(1)  Full text
  13. Hoffer, A  The Discovery of Kryptopyrrole and its Importance in Diagnosis of Biochemical Imbalances in Schizophrenia and in Criminal Behavior.  J Orthomolecular Med 1995; 10(1)  Full text 
  14. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP.  Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.   Schizophr Res. 2002 Nov 1; 58(1): 1-10.  Abstract 
  15. Lerner V, Bergman J, Statsenko N, Miodownik C.  Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.    J Clin Psychiatry. 2004 Nov; 65(11): 1550-4. Abstract 
  16. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.  Am J Psychiatry. 2001 Sep; 158(9): 1511-4.  Abstract |  Full text 
  17. Levine J, Stahl Z, Sela BA, et al.   Homocysteine-Reducing Strategies Improve Symptoms in Chronic Schizophrenic Patients with Hyperhomocysteinemia. Biol Psychiatry. 2006 Jan 17  Abstract 
  18. Li D.  Omega-3 fatty acids and non-communicable diseases. Chin Med J (Engl). 2003 Mar; 116(3): 453-8   Abstract |  Full text 
  19. Mahadik SP, Evans D, Lal H.   Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Apr; 25(3): 463-93. Abstract 
  20. Marchbanks RM, Ryan M, Day IN, Owen M, McGuffin P, Whatley SA.  A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress.   Schizophr Res. 2003 Dec 1; 65(1): 33-8. Abstract 
  21. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders.   Trends Neurosci. 2003 Mar; 26(3): 137-46. Abstract 
  22. Messamore E.  Relationship between the niacin skin flush response and essential fatty acids in schizophrenia.   Prostaglandins Leukot Essent Fatty Acids. 2003 Dec; 69(6): 413-9. Abstract 
  23. Monteleone P, Maj M, Fusco M, et al.  Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics.  Schizophr Res. 1992 Apr; 7(1): 77-84.   Abstract 
  24. Muntjewerff JW, van der Put N, Eskes T, et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia.   Psychiatry Res. 2003 Nov 1; 121(1): 1-9.  Abstract 
  25. Peet M.  Nutrition and schizophrenia: beyond omega-3 fatty acids.  Prostaglandins Leukot Essent Fatty Acids. 2004 Apr; 70(4): 417-22. Abstract 
  26. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002 Jan-Feb; 36(1): 7-18.  Abstract 
  27. Peet M, Stokes C.  Omega-3 Fatty acids in the treatment of psychiatric disorders.   Drugs. 2005; 65(8): 1051-9.  Abstract 
  28.  Pfeiffer Carl C., Ph.D., M.D. and Scott LaMola, B.S.  Zinc and Manganese in the Schizophrenias.    Full text
  29. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients.   Psychiatry Res. 2003 Dec 1; 121(2): 109-22.  Abstract 
  30. Rao AV, Balachandran B.  Role of oxidative stress and antioxidants in neurodegenerative diseases.   Nutr Neurosci. 2002 Oct; 5(5): 291-309 Abstract 
  31. Reddy R, Keshavan M, Yao JK.  Reduced plasma antioxidants in first-episode patients with schizophrenia.   Schizophr Res. 2003 Aug 1; 62(3): 205-12.  Abstract 
  32. Smythies J.  The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.   Neurotox Res. 1999 Sep; 1(1): 27-39. Abstract 
  33. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD.  Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia.   Prostaglandins Leukot Essent Fatty Acids. 2004 Sep; 71(3): 171-6.  Abstract 
  34. Yao JK, Reddy RD, van Kammen DP.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.  CNS Drugs. 2001; 15(4): 287-310.  Abstract 
  35. The Search For An Endogenous Schizotoxin    Full text 
Pyroluria:
 
  1. Pyroluria From Wikipedia, the free encyclopedia.  Full text
  2. Pyroluria  from Digital Naturopath   Full text
  3. Pyroluria  from Dr Kaslow  Full text
  4. Hoffer, A.   The Discovery of Kryptopyrrole and its Importance in Diagnosis of Biochemical Imbalances in Schizophrenia and in Criminal Behavior  Full text 
  5. McGinnis, W.   Pyroluria: Hidden Cause of Schizophrenia, Bipolar, Depression, and Anxiety Symptoms   Full text 
Obsessive-Compulsive Disorder (OCD):
 
  1. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol.   Metab Brain Dis. 2004 Jun; 19(1-2): 125-34.  Abstract 
  2. Durand C, Mary S, Brazo P, Dollfus S.  [Psychiatric manifestations of vitamin B12 deficiency: a case report]    Encephale. 2003 Nov-Dec; 29(6): 560-5. Abstract 
  3. Fux M, Levine J, Aviv A, Belmaker RH.  Inositol treatment of obsessive-compulsive disorder.    Am J Psychiatry. 1996 Sep; 153(9): 1219-21 Abstract |  Full text 
  4. Gelber D, Levine J, Belmaker RH.  Effect of inositol on bulimia nervosa and binge eating.    Int J Eat Disord. 2001 Apr; 29(3): 345-8.  Abstract 
  5. Harvey BH, Brink CB, Seedat S, Stein DJ.  Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1): 21-32 Abstract 
  6. Kaplan BJ, Crawford SG, Gardner B, Farrelly G.   Treatment of mood lability and explosive rage with minerals and vitamins: two case studies in children.   J Child Adolesc Psychopharmacol. 2002 Fall; 12(3): 205-19.    Abstract 
  7. Kim H, McGrath BM, Silverstone PH.  A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies.   Hum Psychopharmacol. 2005 May 6; Abstract 
  8. Levine J.  Controlled trials of inositol in psychiatry.  Eur Neuropsychopharmacol. 1997 May; 7(2): 147-55.  Abstract 
  9. Natural Products in the Clinical Treatment of Mental Illness:  A Profile of Dr. James Greenblatt, MD  [depression, panic disorder, and obsessive-compulsive disorder (OCD)] Full text
Panic Disorder:
  1. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH.  Double-Blind, Placebo-Controlled, Crossover Trial of Inositol Treatment for Panic Disorder. Am J Psychiatry. 1995 Jul; 152(7): 1084-6   Abstract |  Full text
  2. Levine J.  Controlled trials of inositol in psychiatry.  Eur Neuropsychopharmacol. 1997 May; 7(2): 147-55.  Abstract 
  3. Palatnik A, Frolov K, Fux M, Benjamin J.  Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.    J Clin Psychopharmacol. 2001 Jun; 21(3): 335-9.  Abstract 
  4. Natural Products in the Clinical Treatment of Mental Illness:  A Profile of Dr. James Greenblatt, MD  [depression, panic disorder, and obsessive-compulsive disorder (OCD)] Full text
Aggressive Disorder:
  1. Iribarren C, Markovitz JH, Jacobs DR Jr, Schreiner PJ, Daviglus M, Hibbeln JR.  Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults--the CARDIA study.  Eur J Clin Nutr. 2004 Jan; 58(1): 24-31  Abstract
  2. Melvyn R. Werbach, M.D.  Nutritional Influences on Aggressive Behavior.  J Orthomolecular Med 1995; 7(1)   Full text
ADD/ADHD:
  1. Breeding J.   Does ADHD Even Exist?: The Ritalin Sham    Full text 
  2. Haag M. Essential fatty acids and the brain.   Can J Psychiatry. 2003 Apr; 48(3): 195-203.  Abstract 
  3. Harding KL, Judah RD, Gant C.  Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD.   Altern Med Rev. 2003 Aug; 8(3): 319-30.  Abstract |  Full text 
  4. Joshi K, Lad S, Kale M, et al.   Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD).    Prostaglandins Leukot Essent Fatty Acids. 2006 Jan; 74(1): 17-21.    Abstract 
  5. Mousain-Bosc M, Roche M, Rapin J, Bali JP.  Magnesium VitB6 intake reduces central nervous system hyperexcitability in children.  J Am Coll Nutr. 2004 Oct; 23(5): 545S-548S.  Abstract 
  6. Nogovitsina OR, Levitina EV.  [Diagnostic value of examination of the magnesium homeostasis in children with attention deficit syndrome with hyperactivity]   Klin Lab Diagn. 2005 May; (5): 17-9. Abstract 
  7. Richardson AJ.  Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders.   Lipids. 2004 Dec; 39(12): 1215-22.  Abstract 
  8. Stevens L, Zhang W, Peck L, et al.  EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003 Oct; 38(10): 1007-21.  Abstract 
  9. Van Oudheusden LJ, Scholte HR.  Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder.  Prostaglandins Leukot Essent Fatty Acids. 2002 Jul; 67(1): 33-8. Abstract 
Multiple Issues:

The Critical Role of Nutrients in Severe Mental Symptoms
http://www.alternativementalhealth.com/articles/pffeiffer.htm

Biochemical Treatment Of Mental Illness And Behavior Disorders
http://www.hriptc.org/BioTreatment.html
Zinc deficiency:
Zinc Deficiency, Metal Metabolism, And Behavior Disorders  http://www.hriptc.org/zinc_deficiency.html
Biochemical Treatment: Medicines for the Next Century
Walsh WJ.  Biochemical Treatment: Medicines for the Next Century     Full Text
Natural Products in the Clinical Treatment of Mental Illness:  A Profile of Dr. James Greenblatt, MD  [depression, panic disorder, and obsessive-compulsive disorder (OCD)] Full text

Click here to email this page to a friend.
Print this page
Home